Trial Profile
A Phase 2 Prospective, Multi-center, Open-label Trial to Assess the Safety & Efficacy of Cellular Immunotherapy With MDR-103 for Induction of Mixed Chimerism & Immune Tolerance in Past Recipients of HLA Zero-mismatch, LD Kidney Transplants
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs MDR 103 (Primary) ; Antithymocyte globulin; Immunosuppressants
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Medeor Therapeutics
- 17 Oct 2023 Planned initiation date changed from 1 Sep 2023 to 1 Dec 2024.
- 22 Aug 2022 Planned initiation date changed from 1 Sep 2022 to 1 Sep 2023.
- 04 Apr 2022 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.